Get the Stockscreener App
18.10
2.53%
-0.47
Pre-market:
18.79
0.69
+3.81%
Grail Inc stock is traded at $18.10, with a volume of 596.32K.
It is down -2.53% in the last 24 hours and down -18.32% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
See More
Previous Close:
$18.57
Open:
$18.74
24h Volume:
596.32K
Relative Volume:
0.77
Market Cap:
$608.17M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.29%
1M Performance:
-18.32%
6M Performance:
+22.21%
1Y Performance:
+0.00%
1-Day Range:
$17.84
$19.36
1-Week Range:
$16.60
$19.36
52-Week Range:
$12.33
$24.92
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
650-771-9796
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
18.10 | 608.17M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
556.99 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
237.62 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
143.43 | 40.54B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.96 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
418.63 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
Grail Inc Stock (GRAL) Latest News
94,178 Shares in Grail, Inc. (NASDAQ:GRAL) Bought by 180 Wealth Advisors LLC - MarketBeat
GRAIL's Galleri Cancer Test Shows High Patient Satisfaction, Minimal Anxiety in Landmark Study - StockTitan
Trend Tracker for (GRAL) - Stock Traders Daily
Why a Roth IRA is the ‘holy grail’ retirement account—no matter your income - Yahoo Finance
Douglas Lane & Associates LLC Buys New Shares in Grail, Inc. (NASDAQ:GRAL) - MarketBeat
Liquid Biopsy Market Anticipated to Show Positive Growth - openPR
Grail to partner with Premier - LabPulse
Grail kicks off real-world study of multicancer blood test - LabPulse
Grail (NASDAQ:GRAL) Stock Price Down 7.4%Here's What Happened - MarketBeat
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Eastern Progress Online
Arden Theatre Company to Present World Premiere of Holy Grail of Memphis - TheaterMania.com
Short Interest in Grail, Inc. (NASDAQ:GRAL) Rises By 11.9% - MarketBeat
Grail (NASDAQ:GRAL) Trading Down 6.7%Should You Sell? - MarketBeat
Golden Grail Beverages Announces Strategic Update on UPDC Beverages Acquisition - GlobeNewswire
Disappointing week for GRAIL, Inc. (NASDAQ:GRAL) institutional investors who control 48% of the company - Yahoo Finance
Grail: What Lies Ahead After the Illumina Spin-Off - ETF Trends
Here's Why We're Watching GRAIL's (NASDAQ:GRAL) Cash Burn Situation - Simply Wall St
Stocks Showing Improving Market Leadership: GRAIL Earns 83 RS Rating - Investor's Business Daily
GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Eastern Progress Online
Grail (NASDAQ:GRAL) Shares Gap DownHere's What Happened - MarketBeat
How the (GRAL) price action is used to our Advantage - Stock Traders Daily
Illumina And Grail In 2025? Grounds For Optimism, If Mistakes Aren't Repeated (ILMN) - Seeking Alpha
Grail (NASDAQ:GRAL) Shares Down 11.1%Time to Sell? - MarketBeat
GRAIL: Biotech Stock Targeting $100B Cancer Market - MSN
GRAIL to Present at J.P. Morgan Healthcare Conference 2024: Early Cancer Detection Pioneer Takes Stage - StockTitan
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
Remedies After Illumina/GRAIL– The Thorny Question of Proportionality - PYMNTS.com
Grail Blood Test - KOIN.com
Grail (NASDAQ:GRAL) Sets New 52-Week HighHere's Why - MarketBeat
Grail, Inc. (NASDAQ:GRAL) Short Interest Up 15.9% in November - MarketBeat
Function Health Collaborates With GRAIL to Offer Multi-Cancer Early Detection Test Nationwide - The Eastern Progress Online
Grail: Lack Of Near Term Catalyst, Market Likely To Lose Interest Soon (NASDAQ:GRAL) - Seeking Alpha
Golden Grail Beverages buys US co-packer UPDC Beverages - Yahoo Finance
Golden Grail Beverages to acquire United Product Development Corp. - Food Business News
Golden Grail Beverages Announces the Acquisition of UPDC Beverages - GlobeNewswire
Golden Grail Beverages Expands Portfolio with Strategic Acquisition of Profitable Co-Packing Powerhouse UPDC - StockTitan
GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4) - The Eastern Progress Online
Liquid Biopsy Market Poised for Substantial Growth (2024-2031) - openPR
Grail (NASDAQ:GRAL) Hits New 52-Week HighTime to Buy? - MarketBeat
GRAIL to Participate in Upcoming Investor Conferences - Kilgore News Herald
New blood test capable of screening for over 50 cancers available in Canada - Mugglehead
Function Health and GRAIL Collaborate to Make Multi-Cancer Early Detection Test More Accessible - HIT Consultant
Grail, Inc. (NASDAQ:GRAL) Short Interest Update - MarketBeat
GRAIL Awards 115K Shares in Equity Incentives to Attract Top Talent in Latest Hiring Push - StockTitan
Blood test that can screen for 50+ cancers now for sale in Canada, at $2,099 - CBC News
California startup finds early success with experimental blood test to detect many cancers - Martinsville Bulletin
Grail initiated at equal weight by Morgan Stanley - MSN
Grail initiated at equal weight by Morgan Stanley (NASDAQ:GRAL) - Seeking Alpha
Morgan Stanley cautious on GRAIL stock despite $100B market opportunity - Investing.com
Grail (NASDAQ:GRAL) Coverage Initiated by Analysts at Morgan Stanley - MarketBeat
Grail initiated with an Equal Weight at Morgan Stanley - TipRanks
Grail Inc Stock (GRAL) Financials Data
There is no financial data for Grail Inc (GRAL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.17%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):